Recent Updates
Recently added Catalysts
NXGL Positive Sentiment Score: 85/100

NEXGEL Reports Record Fourth Quarter and Full Year 2024 Financial Results Fourth quarter 2024 revenue totaled $3.04 million, an increase of 181%, as compared to $1.08 million for the same period the prior year Full year

Key Takeaway: NEXGEL, Inc. reported record financial results for the fourth quarter and full year 2024. The company achieved significant revenue growth, with fourth quarter revenue reaching $3.04 million, and full year revenue totaling $8.69 million, increases of 181% and 112% year-over-year, respectively. Despite these gains, NEXGEL incurred a net loss of $3.28 million for the year, slightly higher than the previous year's loss. Looking ahead, the company anticipates at least $13 million in revenue for 2025 and expects to achieve positive EBITDA.

Market Sentiment Analysis

POSITIVE FACTORS

  • Fourth quarter 2024 revenue surged to $3.04 million, a 181% increase year-over-year.
  • The full year revenue totaled $8.69 million, demonstrating a 112% growth compared to 2023.
  • NEXGEL expects positive EBITDA in 2025 and anticipates revenue of at least $13 million.

CONCERNS & RISKS

  • The company reported a net loss of $3.28 million in 2024, up from a loss of $3.16 million in 2023.
  • Operating expenses increased significantly, driven by higher administrative costs and advertising fees.

Full Press Release Details

Reports Record Fourth Quarter and Full Year 2024 Financial Results
quarter 2024 revenue totaled $3.04 million, an increase of 181%, as compared to $1.08 million for the same period the prior year
year 2024 revenue totaled $8.69 million, an increase of 112%, as compared to $4.09 million in 2023
100% full year and fourth quarter revenue growth year-over-year for third consecutive year
issues revenue guidance of $13 million for 2025 and expects to achieve positive EBITDA during the year
Pa. - March 24, 2025 - NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"),
a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced record
fourth quarter and full year financial results for the period ending December 31, 2024.
Quarter 2024 Financial Highlights:
Year 2024 Financial Highlights:
fourth quarter and full year 2024 were record periods for NEXGEL across all our key financial measures. We successfully grew full year
and fourth quarter revenue over 100% year-over-year for the third consecutive year Our EBITDA loss continued to narrow when compared
to Q4 2023. Our growth and operational efficiency were driven by consistent performance each quarter in both branded consumer products
and contract manufacturing," Adam Levy, NEXGEL's Chief Executive Officer, commented. "During the fourth quarter we
made our first shipments of SilverSeal to Cintas, which continues into the first quarter of 2025. Our consumer products
across our entire portfolio of brands including Medagel, Silly George , Kenkoderm , and Histasolv, in partnership
with STADA, all performed well. In an ongoing effort to optimize our brand portfolio, we are leveraging our marketing capabilities, while
also launching new product offerings for our loyal customers."
Levy continued, "As we look into the first quarter 2025, which is seasonally our weakest of the year, we expect revenue to be at
least $2.75 million. We also expect to generate at least $13 million in revenue for 2025 and achieve positive EBITDA during the year.
Our pipeline of potential new customers in 2025 remains healthy and robust."
Operating Highlights:
Quarter and Full Year 2024 Financial Results
the fourth quarter of 2024, revenue totaled $3.04 million, an increase of 181%, as compared to $1.08 million for the fourth quarter 2023.
Revenue for the full year 2024 totaled $8.69 million, an increase of 112%, as compared to $4.09 million in 2023. The increase year-over-year
in overall revenue during both periods was primarily due to sales growth in branded consumer products and contract manufacturing.
of revenues totaled $1.91 million for the fourth quarter 2024, as compared to $0.99 million for the fourth quarter 2023. Cost of revenues
in 2024 totaled $5.94 million, as compared to $3.72 million in 2023. The increase in cost of revenues is primarily aligned with sales
of branded consumer products, as both Silly George and Kenkoderm were acquired after the comparable 2023 period.
profit totaled $1.13 million for the fourth quarter of 2024, as compared to a gross profit of $0.09 million for the fourth quarter of
2023. Gross profit margin for the fourth quarter 2024 was 37.2%, as compared to 8.7% for the fourth quarter 2023. Gross profit for 2024
totaled $2.75 million, as compared to $0.37 million in 2023. Gross profit margin for 2024 was 31.6%, as compared to 9.2% in 2023. The
increase of $2.38 million in 2024 was primarily due to an increase in branded consumer products.
general and administrative expenses totaled $1.97 for the fourth quarter 2024, as compared to $1.30 for the fourth quarter 2023. Selling,
general and administrative expenses totaled $6.22 million for 2024, as compared to $3.75 million in 2023. The increase year-over-year
was attributable to increases in compensation and benefits, share-based compensation, advertising, marketing and Amazon fees, professional
and consulting fees, and other expenses, offset by decreases in investor and shareholder services and franchise taxes and corporate insurance.
a non-GAAP financial measure, totaled ($0.73). million for the fourth quarter of 2024 as compared to ($.97) million for the fourth quarter
of 2023. EBITDA for 2024 totaled ($2.76) million as compared to ($2.92) million in 2023.
EBITDA1, a non-GAAP financial measure, totaled ($0.62) million for the fourth quarter 2024 as compared to ($0.88) million
for the fourth quarter 2023. Adjusted EBITDA for 2024 totaled ($2.43) million as compared to ($2.80) million for 2023.
loss for the fourth quarter of 2024 was $0.85 million, as compared to a net loss of $1.10 million for the fourth quarter of 2023.
Net loss for 2024 totaled $3.28 million as compared to a net loss of $3.16 million in 2023. Of note, our fourth quarter net loss includes
two inventory write offs totaling $243 thousand that are one-time in nature. One write-off of $197 thousand related to high minimum order
quantity inventory purchases in 2022 for SilverSeal and Turf Guard 2x3. High minimum order quantities were a significant challenge to
launching new products and were one of the motivating factors for our Q1 2023 joint venture with CG Converting and Packaging, which now
allows us to control the manufacturing process and, as a result, we do not expect any future write-offs. The second is for $46 thousand
for additional excess and obsolete inventory.
of December 31, 2024, the Company had a cash balance of approximately $1.81 million.
of March 24, 2025, NEXGEL had 7,654,038 shares of common stock outstanding.
EBITDA and Adjusted EBITDA are a non-GAAP measures described in the section titled Non-GAAP Financial Measures" below and
reconciled to the most directly comparable GAAP measures at the end of this release.
Quarter and Full Year 2024 Financial Results Conference Call
Call: 1-800-245-3047 (U.S. Toll Free) or 1-203-518-9765 (International)
Events and Presentations
interested individuals unable to join the conference call, a replay will be available through April 3, 2025, by dialing 1-844-512-2921
(U.S. Toll Free) or 1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 11158402.
An archive of the webcast will also be available for 90 days.
is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels.
Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL
brands include SilverSeal , Hexagels , Turfguard , Kenkoderm and Silly George .
Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.
Non-GAAP financial measures are included in this press release. In the calculation of these measures, the Company excludes certain items,
such as amortization of intangible assets, stock-based compensation, tax impact of adjustments, other unusual items and discrete items
impacting income tax expense. The Company believes that excluding such items provides investors and management with a representation
of the Company's core operating performance and with information useful in assessing its prospects for the future and underlying
trends in the Company's operating expenditures and continuing operations. Management uses such Non-GAAP measures to evaluate financial
results and manage operations. The release and the attachments to this release provide a reconciliation of each of the Non-GAAP measures
referred to in this release to the most directly comparable GAAP measure. The Non-GAAP financial measures are not meant to be considered
a substitute for the corresponding GAAP financial statements and investors should evaluate them carefully. These Non-GAAP financial measures
may differ materially from the Non-GAAP financial measures used by other companies.
press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") (which Sections were adopted as part
of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words "believe,"
"anticipate," "estimate," "expect," "intend," "plan," "project,"
"prospects," "outlook," and similar words or expressions, or future or conditional verbs, such as "will,"
"should," "would," "may," and "could," are generally forward-looking in nature and not
historical facts, including, without limitation, our expectation that our revenue will be at least $2.8 million in the first quarter
of 2025 and our expectation to generate at least $13 million in revenue for 2025 and achieve positive cash flow from operations during
the year. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's
actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for
many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether
as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's
forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2024, including
but not limited to the discussion under "Risk Factors" therein, which the Company filed with the SEC and which may be viewed
Pinto, Managing Director
Strategic Communications
thousands, except share and per share data)
December 31, 2024 December 31, 2023
ASSETS:
Current Assets:
Cash $ 1,807 $ 2,700
Accounts receivable, net 933 633
Inventory 1,751 1,319
Prepaid expenses and other current assets 623 400
Total current assets 5,114 5,052
Goodwill 1,128 1,128
Intangibles, net 807 326
Property and equipment, net 2,211 1,499
Operating lease - right of use asset 1,628 1,855
Other assets 95 95
Total assets $ 10,983 $ 9,955
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts payable $ 761 $ 579
Accounts payable - related party 531 654
Accrued expenses and other current liabilities 310 398
Deferred revenue 179 20
Current portion of note payable 97 80
Warrant liability 118 146
Contingent consideration liability 178 439
Finance lease liability, short term 59 -
Operating lease liability, current portion 237 233
Total current liabilities 2,470 2,549
Operating lease liability, net of current portion 1,538 1,727
Finance lease liability, long term 307 -
Notes payable, net of current portion 588 513
Total liabilities 4,903 4,789
Commitments and Contingencies (Note 17)
STOCKHOLDERS' EQUITY
Preferred stock, par value $0.001 per share, 5,000,000 shares authorized, no shares issued and outstanding - -
Common stock, par value $0.001 per share, 25,000,000 shares authorized; 7,638,497 and 5,741,838 shares issued and outstanding as of December 31, 2024 and 2023, respectively 8 6
Additional paid-in capital 23,743 19,406
Accumulated deficit (17,996 ) (14,715 )
Total NexGel stockholders' equity 5,755 4,697
Non-controlling interest in joint venture 325 469
Total stockholders' equity 6,080 5,166
Total liabilities and stockholders' equity $ 10,983 $ 9,955
STATEMENTS OF OPERATIONS
thousands, except share and per share data)
Year Ended December 31,
2024 2023
Revenues, net $ 8,688 $ 4,089
Cost of revenues 5,940 3,715
Gross profit 2,748 374
Operating expenses
Research and development 78 103
Selling, general and administrative 6,224 3,748
Total operating expenses 6,302 3,851
Loss from operations (3,554 ) (3,477 )
Other income (expense)
Change in fair value of warrant liability, net of warrant modification expense 28 96
Realized gain on investments in marketable securities 68 191
Interest expense, net (81 ) (15 )
Change in fair value of contingent consideration (18 ) -
Other expense (4 ) (2 )
Other income 98 19
Total other income (expense), net 91 289
Loss before income taxes (3,463 ) (3,188 )
Income tax expense - -
Net loss (3,463 ) (3,188 )
Less: Loss attributable to non-controlling interest in joint venture 182 31
Net loss attributable to NexGel stockholders $ (3,281 ) $ (3,157 )
Net loss per common share - basic and diluted $ (0.50 ) $ (0.56 )
Weighted average shares used in computing net loss per common share - basic and diluted 6,511,574 5,671,842
STATEMENTS OF CASH FLOWS
Year Ended December 31,
2024 2023
Operating Activities
Net loss $ (3,281 ) $ (3,157 )
Adjustments to reconcile net loss to net cash used in operating activities:
Loss attributable to non-controlling interest in joint venture (182 ) (31 )
Depreciation and amortization 436 226
Share-based compensation 367 217
Realized gain on investment in marketable securities (68 ) (191 )
Change in fair value of warrant liability (28 ) (125 )
Change in fair value of contingent consideration 18 -
Amortization of right of use asset 42 217
Warrant modification expense - 29
Changes in operating assets and liabilities:
Accounts receivable, net (300 ) (411 )
Inventory (432 ) (760 )
Prepaid expenses and other current assets (223 ) (260 )
Accounts payable 182 314
Accounts payable - related party (123 ) 654
Accrued expenses and other current liabilities (434 ) 22
Deferred revenue 159 20
Net Cash Used in Operating Activities (3,867 ) (3,236 )
Investing Activities
Purchases of equipment (443 ) (696 )
Investment in subsidiary (400 ) (547 )
Proceeds from sales of marketable securities 68 5,699
Net Cash Provided by (Used in) Investing Activities (775 ) 4,456
Financing Activities
Principal payments on operating lease liability - (175 )
Proceeds from notes payable - 315
Payment of contingent consideration (279 ) -
Proceeds from rights offering 3,772 -
Principal payments of notes payable (77 ) (6 )
Proceeds from non-controlling interest 38 -
Principal payment of financing lease liability (50 ) -
Proceeds from margin line of credit 345 245
Net Cash Provided by Financing Activities 3,749 379
Net Increase (Decrease) in Cash (893 ) 1,599
Cash - Beginning of year 2,700 1,101
Cash - End of year $ 1,807 $ 2,700
Supplemental Non-cash Investing and Financing Activities
Shares issued in conjunction with asset acquisition $ 200 $ -
Property and equipment financed under notes payable $ 169 $ -
Property and equipment financed under financing leases $ 416 $
Property and equipment contributed as capital investment to JV $ - $ 500
ROU asset and operating lease liabilities recognized upon consolidation of JV $ - $ 334
OF SELECTED GAAP MEASURES TO NON-GAAP MEASURES
thousands, except per share amounts)
OF EBITDA & ADJUSTED EBITDA
Three Months Ended September 30, Three Months Ended December 31,
2024 2024 2023
Amount Amount Amount
Net (loss) income: $ (754 ) $ (824 ) $ (1,187 )
Less: Loss (income) attributable to non-controlling interest in joint venture 61 (26 ) 89
Net loss attributable to NexGel stockholders (693 ) (850 ) (1,098 )
Adjustments:
Depreciation and amortization 184 108 123
Interest expense, net 20 16 3
EBITDA (489 ) (726 ) (972 )
Change in warrant liability (1) (11 ) 9 -
Share-based compensation expense (2) 153 96 97
Adjusted EBITDA: $ (347 ) $ (621 ) $ (875 )
Year Ended December 31,
2024 2023
Amount Amount
Net (loss) income: $ (3,463 ) $ (3,188 )
Less: Loss (income) attributable to non-controlling interest in joint venture 182 31
Net loss attributable to NexGel stockholders (3,281 ) (3,157 )
Adjustments:
Depreciation and amortization 436 226
Interest expense, net 81 15
EBITDA (2,764 ) (2,916 )
Change in warrant liability (1) (28 ) (96 )
Share-based compensation expense (2) 367 217
Adjusted EBITDA: $ (2,425 ) $ (2,795 )

Frequently Asked Questions

What were NEXGEL's fourth quarter 2024 revenues?

NEXGEL's fourth quarter 2024 revenue was $3.04 million, up 181% from 2023.

How much did NEXGEL earn for the full year 2024?

For the full year 2024, NEXGEL earned $8.69 million, a 112% increase from 2023.

What revenue guidance did NEXGEL issue for 2025?

NEXGEL projected revenue of $13 million for 2025 and expects positive EBITDA.

How much loss did NEXGEL report for Q4 2024?

NEXGEL reported a loss of $0.85 million for the fourth quarter of 2024.

What is NEXGEL's gross profit margin for 2024?

NEXGEL's gross profit margin for 2024 was 31.6%, compared to 9.2% in 2023.

Last updated: Mar 24, 2025